In a test of drug sensitivity in lung cancer patients, the researchers screened 26 antitumor drugs using lung cancer organoids and found that organoids with mutations in EGFR responded to gefitinib and osimertinib differently (Chen J H et al., 2020). The gene discussed is EGFR; the disease is lung cancer.